Omega Funds

Activity in this selectionBiotech

By stage

Series A2

Series B1

Biotech3

United States2

Switzerland1

3 in this selection

Aug 11

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries B

Role not disclosed

Feb 4

Develops novel multifunctional antibodies for oncology and immunology & inflammation indications

$52MSeries A+

Role not disclosed

Jan 14

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1

Role not disclosed